Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target raised to $60 from $46 at H.C. Wainwright
- Dyne Therapeutics Reports Positive Phase 1/2 Trial Results
- Dyne Therapeutics reports ‘positive’ results from Phase 1/2 DELIVER trial
- Dyne Therapeutics price target raised to $21 from $12 at Bernstein
- Dyne Therapeutics price target lowered to $17 from $18 at JPMorgan